Dr. Nikola Baumann discusses the role of blood-based prognostic testing in improving access for MASLD/MASH patient care
How neurology biomarkers are moving from CSF and PET into accessible blood tests for Alzheimer’s disease and neurodegenerative disease care
Advancing Alzheimer's disease research with innovative plasma Tau biomarkers and automated, high-throughput assay workflows
At AAIC 2026, Dr. Ashton Harper, Roche Diagnostics, discusses how pTau217 could help reshape Alzheimer’s testing across primary and secondary care
